1. Home
  2. ENVB vs BJDX Comparison

ENVB vs BJDX Comparison

Compare ENVB & BJDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENVB
  • BJDX
  • Stock Information
  • Founded
  • ENVB 1994
  • BJDX 2015
  • Country
  • ENVB United States
  • BJDX United States
  • Employees
  • ENVB N/A
  • BJDX N/A
  • Industry
  • ENVB Biotechnology: Pharmaceutical Preparations
  • BJDX Medical Specialities
  • Sector
  • ENVB Health Care
  • BJDX Health Care
  • Exchange
  • ENVB Nasdaq
  • BJDX Nasdaq
  • Market Cap
  • ENVB 3.1M
  • BJDX 2.9M
  • IPO Year
  • ENVB N/A
  • BJDX 2021
  • Fundamental
  • Price
  • ENVB $1.32
  • BJDX $1.58
  • Analyst Decision
  • ENVB Strong Buy
  • BJDX
  • Analyst Count
  • ENVB 1
  • BJDX 0
  • Target Price
  • ENVB $10.00
  • BJDX N/A
  • AVG Volume (30 Days)
  • ENVB 107.1K
  • BJDX 51.0K
  • Earning Date
  • ENVB 08-11-2025
  • BJDX 08-13-2025
  • Dividend Yield
  • ENVB N/A
  • BJDX N/A
  • EPS Growth
  • ENVB N/A
  • BJDX N/A
  • EPS
  • ENVB N/A
  • BJDX N/A
  • Revenue
  • ENVB N/A
  • BJDX N/A
  • Revenue This Year
  • ENVB N/A
  • BJDX N/A
  • Revenue Next Year
  • ENVB N/A
  • BJDX $55.56
  • P/E Ratio
  • ENVB N/A
  • BJDX N/A
  • Revenue Growth
  • ENVB N/A
  • BJDX N/A
  • 52 Week Low
  • ENVB $1.01
  • BJDX $1.46
  • 52 Week High
  • ENVB $11.55
  • BJDX $37.50
  • Technical
  • Relative Strength Index (RSI)
  • ENVB 57.52
  • BJDX 43.21
  • Support Level
  • ENVB $1.19
  • BJDX $1.60
  • Resistance Level
  • ENVB $1.28
  • BJDX $1.69
  • Average True Range (ATR)
  • ENVB 0.06
  • BJDX 0.07
  • MACD
  • ENVB 0.02
  • BJDX 0.01
  • Stochastic Oscillator
  • ENVB 91.48
  • BJDX 30.00

About ENVB Enveric Biosciences Inc.

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

About BJDX Bluejay Diagnostics Inc.

Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.

Share on Social Networks: